Back to Search

Phase I Trial of MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma

  • Protocol Number: 202502144
  • Principal Investigator: Khushman, Moh'd
  • Cancer Types: Gastrointestinal

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

The investigators hypothesize that MK2 inhibition may improve efficacy of mFOLFIRINOX chemotherapy for patients with pancreatic ductal adenocarcinoma (PDAC).

Protocol Interventions

Drug: Zunsemetinib, Drug: mFOLFIRINOX